📰🧠🔬 SPINE CORD INJURY STUDY HIGHLIGHTS – NeuroAiD™II (MLC901) Evaluation for Neuroprotection and Neuroregeneration in a Preclinical Spinal Cord Injury Model.

Spinal cord injury (SCI) is a severe condition with limited therapeutic options. A recent preclinical study by Anjum et al. (2025) highlights the significant neuroprotective and neuroregenerative effects of NeuroAiD™ II (MLC901) in a kainic acid-induced SCI model.

NeuroAiD™II (MLC901) administration led to marked improvements in motor and sensory function, enhanced nerve conduction, axonal regeneration, and tissue preservation. These effects reflect NeuroAiD’s established multimodal mechanisms in brain injuries, supporting neuroprotection, neuroplasticity, and repair.

Clinical relevance is supported by the SATURN study (Kumar et al., 2023), which demonstrated the safe use of NeuroAiD™II in patients with severe SCI, reinforcing its potential role in neurorehabilitation strategies.

📄 Access the full study at:
Anjum, A., Yazid, M.D., Daud, M.F. et al. Evaluation of Neuroprotective and Neuroregenerative Potential of NeuroAiD™ II(MLC901) in a Rat Model of Kainic Acid-Induced Spinal Cord Injury. Mol Neurobiol (2025). https://link.springer.com/article/10.1007/s12035-025-05064-4. This is an open-access article under a CC-BY 4.0 license.

📄 Access the full SATURN study at:
Kumar, R., Htwe, O., Baharudin, A., et al. Long-Term Outcomes of the Spinal Cord Injury Assessing Tolerability and Use of Combine Rehabilitation and NeuroAID (SATURN STUDY). Journal of Spine Research and Surgery . 5 (2023): 19-25. https://www.fortunejournals.com/articles/longterm-outcomes-of-the-spinal-cord-injury-assessing-tolerability-and-use-of-combine-rehabilitation-and-neuroaid-saturn-study.html. This is an open-access article under a CC-BY 4.0 license.